Hypermethylation of the PARK2 promoter correlated with shortened patient survival in prostate (PRAD) and pancreatic (PAAD) adenocarcinoma, low-grade glioma (LGG), liver hepatocellular carcinoma (LIHC) and paraganglioma/pheochromocytoma (PCPG) (Figure 2C). Here, PRKN is linked to paraganglioma.